Drug
Nivolumab
Nivolumab: highest development phase Phase 3, developed by BeyondSpring, Bristol-Myers Squibb, Dynavax Technologies and others. 15 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BeyondSpring, Bristol-Myers Squibb, Dynavax Technologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nivolumab NCT06561386 | Phase 3 | Non-small Cell Lung Cancer |
| Nivolumab NCT03906071 | Phase 3 | Metastatic Non-Squamous Non-Small Cell Lung Cancer |
| Nivolumab NCT03341936 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck |
| Nivolumab NCT03420521 | Phase 2 | Neuroendocrine Tumors |
| Nivolumab NCT03899155 | Phase 2 | Cancer |
| Nivolumab, Surgery, Radiotherapy NCT03721757 | Phase 2 | Squamous Cell Carcinoma of the Oral Cavity |
| Nivolumab NCT04007588 | Phase 2 | Melanoma Stage III |
| Nivolumab NCT03316586 | Phase 2 | Breast Cancer |
| Nivolumab NCT03171025 | Phase 2 | Bladder Cancer |
| Nivolumab NCT04204837 | Phase 2 | Squamous Cell Carcinoma of the Skin |
| Nivolumab NCT03575793 | Phase 1/2 | Lung Cancer |
| Nivolumab NCT04098432 | Phase 1/2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma |
| Nivolumab NCT04061863 | Phase 1/2 | Metastatic Breast Cancer |
| Nivolumab NCT02652455 | Phase 1 | Melanoma (Skin) |
| Nivolumab NCT04050085 | Phase 1 | Metastatic Pancreatic Adenocarcinoma |
Latest
Follow Nivolumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.